📋 Sai Parenteral's Ltd IPO 2026 — Date, Price Band, GMP & Allotment
Sai Parenteral's Ltd IPO is a Mainboard book-built issue that opened on 24 March 2026 and closed on 27 March 2026. The company raised ₹408.79 Crore through this public offering at a price band of ₹372–₹392 per share. The Sai Parenteral's IPO allotment was finalised on 30 March 2026 and shares listed on NSE & BSE on 2 April 2026.
🏢 About Sai Parenteral's Ltd — Company Overview
Incorporated in 2001 and headquartered in Hyderabad, Telangana, Sai Parenteral's Ltd is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing. The company operates in two segments — Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) services for domestic and international markets.
The product portfolio covers cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, vitamins and supplements, analgesics, and dermatology therapeutic areas. Products are available in injectables, tablets, capsules, liquid orals, and ointments dosage forms. Sai Parenteral's operates 5 manufacturing facilities — 4 in Hyderabad and 1 in Ongole (Andhra Pradesh) through its subsidiary Revat Laboratories — with combined installed capacity of 1,160 million units per year. The company exports to Australia, New Zealand, Southeast Asia, the Middle East, and Africa.
📊 Sai Parenteral's IPO Details at a Glance
◆ Exchange: NSE & BSE (Mainboard)
◆ Issue Type: Book Built Mainboard IPO (Fresh Issue + OFS)
◆ Price Band: ₹372 – ₹392 per share
◆ Face Value: ₹5 per share
◆ Lot Size: 38 shares
◆ Minimum Investment (Retail): ₹14,896 (1 lot = 38 shares)
◆ Minimum Investment (sNII): ₹2,08,544 (14 lots = 532 shares)
◆ Issue Size: ₹408.79 Crore (1,04,28,288 shares)
◆ Fresh Issue: ₹285 Crore (72,70,408 shares)
◆ Offer for Sale: ₹123.79 Crore (31,57,880 shares)
◆ Lead Manager: Arihant Capital Markets Ltd
◆ Registrar: Bigshare Services Pvt. Ltd.
📅 Sai Parenteral's IPO Timeline — Important Dates
◆ Anchor Investor Date: 23 March 2026 — Raised ₹122.64 Crore
◆ IPO Open Date: 24 March 2026
◆ IPO Close Date: 27 March 2026
◆ Allotment Date: 30 March 2026
◆ Refund Initiation: 1 April 2026
◆ Demat Credit: 1 April 2026
◆ Listing Date: 2 April 2026 (Thursday) — NSE & BSE
📈 Sai Parenteral's IPO GMP Today
Check the latest Sai Parenteral's IPO GMP today live on IPOView. GMP is unofficial and should not be the sole basis of investment decisions.
💰 Sai Parenteral's IPO Subscription Status
The Sai Parenteral's IPO subscription status showed an overall subscription of 1.05 times at close. QIB category was subscribed 1.71 times, NII 2.36 times, and retail 0.116 times indicating retail undersubscription offset by strong institutional demand.
📑 Sai Parenteral's IPO Financials
◆ Total Income FY23: ₹97.03 Crore
◆ Total Income FY24: ₹155.18 Crore
◆ Total Income FY25: ₹163.74 Crore
◆ PAT FY23: ₹4.38 Crore
◆ PAT FY24: ₹8.42 Crore
◆ PAT FY25: ₹14.45 Crore — consistent growth
◆ EBITDA FY25: ₹39.44 Crore
◆ Manufacturing Capacity: 1,160 million units/year
Sai Parenteral's IPO — Strengths
🔹 Diversified Formulations + CDMO Model — Two revenue streams reduce dependency on single segment.
🔹 5 Accredited Manufacturing Facilities — Global accreditations enable export to regulated markets.
🔹 Consistent PAT Growth — PAT grew from ₹4.38 Cr (FY23) to ₹14.45 Cr (FY25), 3x in 2 years.
🔹 International Expansion — Acquiring Noumed Pharmaceuticals (Australia) via Singapore subsidiary.
🔹 Strong CDMO Focus — Growing CDMO revenue share adds higher-margin business mix.
🔹 298 Full-time Employees with dedicated R&D team of 34 and quality control team of 41.
⚠️ Sai Parenteral's IPO — Risks
🔸 Retail Undersubscription — Retail quota subscribed only 0.116 times indicating weak retail demand.
🔸 Acquisition Integration Risk — Noumed Pharmaceuticals acquisition adds execution risk.
🔸 Regulatory Risk — Pharma sector subject to stringent CDSCO and international regulatory compliance.
🔸 Small PAT Base — ₹14.45 Crore PAT on ₹408.79 Crore issue size implies premium valuation.
🔍 Sai Parenteral's IPO — Conclusion
The Sai Parenteral's Ltd IPO brings a growing pharma formulations and CDMO company with global accreditations and international expansion plans to the public markets. Track Sai Parenteral's IPO allotment status, GMP and listing price on IPOView. Also check all 2026 IPOs on IPOView.